VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study - Treatment with highest dosing regimen of VX-787 reduced viral...
A variety of different methods for the evaluation of antiviral agents in cell culture systems are briefly reviewed. It has been repeatedly noted that many test conditions such as the cell culture system, virus strain, virus challenge dose, virus input multiplicity of infection, and time of harvesting, etc., can substantially affect or even alter the test results, thus making comparative studies and unambiguous evaluations very difficult. Attempts are made to discuss previous test methods together with our recent studies with the aim to simplify test procedures and assay methods. Suggestions are proposed for in vitro evaluation of new antiviral agents. It is hoped that this review will alarm investigators to the problems of assaying new antiviral agents. If the suggestions made in this review can be followed, the screening of the enormous number of promising antiviral compounds may be made more efficiently in the near future.
Hepatitis C virus, which infects the liver and certain immune cells, leads to serious liver diseases such as cirrhosis and liver cancer more frequently than any other form of hepatitis. HCV is an RNA virus known to undergo a high rate of mutation that may help it both to avoid control by the immune system and to develop resistance to direct antiviral medications. According to the World Health Organization, HCV infects approximately 170 million people worldwide, including at least 2.7 million in the United States, and 10-20 percent of those chronically infected with HCV will ultimately develop liver cirrhosis, making HCV the leading cause of liver transplants in the United States. The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually from HCV-related cirrhosis or liver cancer. Coley believes, there is an unmet need for therapies with better side effect profiles and equivalent or superior efficacy, especially in the difficult-to-treat population of ...
Until 2011, the combination of pegylated interferon (pINF) and ribavirin (RBV) for 24 or 48 weeks was the approved treatment for chronic hepatitis C (CHC). Telaprevir and boceprevir, licensed in 2011 for use in patients infected with HCV genotype 1, were the first direct-acting antiviral agents (DAAs). With combinations including these agents, higher sustained viral response (SVR) rates were achieved compared with pINF+RBV, but also higher side effects. In 2013, sofosbuvir (SOF) was approved for use in HCV-infected patients with genotypes 2 and 3 in combination with RBV, and in those with genotypes 1 and 4, in combination with pINF and RBV with SVR rates ,90%.1 ,2 With approval of other oral DAAs such as simeprevir and daclatasvir, now highly efficacious interferon-free regimens are also prescribed, particularly in genotypes 1 and 4.3 ,4 Moreover, last week, the European Commission granted marketing authorisation for the SOF-ledipasvir combination (Harvoni), the first single-tablet ...
Stable integration of HIV proviral DNA into host cell chromosomes, a hallmark and essential feature of the retroviral life cycle, establishes the infection permanently. Current antiretroviral combination drug therapy cannot cure HIV infection. However, expressing an engineered HIV-1 long terminal repeat (LTR) site-specific recombinase (Tre), shown to excise integrated proviral DNA in vitro, may provide a novel and highly promising antiviral strategy. We report here the conditional expression of Tre-recombinase from an advanced lentiviral self-inactivation (SIN) vector in HIV-infected cells. We demonstrate faithful transgene expression, resulting in accurate provirus excision in the absence of cytopathic effects. Moreover, pronounced Tre-mediated antiviral effects are demonstrated in vivo, particularly in humanized Rag2−/−γc−/− mice engrafted with either Tre-transduced primary CD4+ T cells, or Tre-transduced CD34+ hematopoietic stem and progenitor cells (HSC). Taken together, our data ...
Volume 34, Issue Supplement s1, pages 38-45, February 2014. Review Article. You have free access to this content. Vincenzo Boccaccio, Savino Bruno*. Article first published online: 23 DEC 2013. DOI: 10.1111/liv.12391. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Keywords: boceprevir; direct acting antivirals; faldaprevir; HCV-related cirrhosis; hepatitis C virus; simeprevir; sofosbuvir; sustained virological response; telaprevir. Abstract. In recent years, several studies have clearly shown that sustained virological response (SVR) achieved by interferon-based therapies may delay or reduce the risk of hepatocellular carcinoma, liver decompensation and all-causes of mortality in all categories of patients with HCV-related cirrhosis, a condition characterized by a wide heterogeneity of clinical features, especially in patients with compensated disease. Unfortunately, the advanced fibrosis stage has been shown to be associated with poor SVR rates and poor tolerance with ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with VX-787 in a Phase 2 influenza challenge study resulted in statistically significant improvements in viral and clinical measurements......VRTX
Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which
An unexpected increased HCC recurrence and occurrence rate among HCV patients treated with direct acting antivirals combination has been reported. Aim of the study was the evaluation of early HCC occurrence rate and its risk factors in a HCV infected population, treated with direct-acting-antivirals. According to the Italian ministerial guidelines for direct-acting-antivirals treatment, 1022 consecutive HCV patients treated with direct-acting-antivirals were enrolled. Patients either with active HCC at imaging or history of previous treated HCC, HBV or HIV co-infection, or liver transplant recipients were excluded. The SVR, defined as the persistent absence of detectable serum HCV-RNA 12 weeks after the end of treatment (SVR12), was assessed for all enrolled patients. Abdominal ultrasound was performed before starting antiviral therapy, and repeated every 6 months. HCC was diagnosed according to the international guidelines. Patients showing either nodular patterns suggestive of HCC or with uncertain
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic v
Aseptic loosening (AL) because of osteolysis may be the primary reason behind joint prosthesis failure. the next factors were noticed: Interleukins 6 and 1 (IL16 and ), Tumor Necrosis Element (TNF), nuclear element kappa-light-chain-enhancer of triggered B cells (NFB), Nuclear element of triggered T-cells, cytoplasmic 1 (NFATC1), Cathepsin K (CATK) and Tartrate-resistant acidity phosphatase (Capture). Titanium (Ti) and Polyethylene (PE) had been the most researched contaminants, displaying that Ti up-regulated osteoclastogenesis and swelling related genes, while PE up-regulated osteoclastogenesis related genes mainly. in ZrO2 than Ti[54]0.05, 0.5, 1 mg/mL Ti alloy contaminants (? 0.52 m)SFs from OA pzProtein amounts (IRE1-, CHOP, RANKL, OPG, sRANKL) Gene expression ((at the best concentration)[45]0.1 mg/mL Ti particles (? 3.6 m)Mice BMMOCs number Bone resorption assay Gene expression ( cell viability, ALP, COLL I, OCN, mineralization, CMKBR7 membrane damage viability OBs, BMMs: (at 7 days), (at ...
Treatment strategies aimed to achieve sustained virologic response (SVR) are of highest priority in patients with chronic hepatitis C and HIV coinfection, since SVR leads to a dramatic reduction in the incidence of hepatic decompensations and mortality in this setting. Until recently, therapy against hepatitis C virus (HCV) was based on pegylated interferon (peg-IFN) plus ribavirin (RBV). This combination prompt SVR only in approximately 50% of the HCV genotype 1 (HCV-1)-infected patients. Furthermore, it is costly and associated with multiple and sometimes serious side effects. In the setting of HIV/HCV-1-coinfection, rates of SVR are even lower and do not exceed 25% in the clinical practice.. Considerable increases of SVR have been achieved recently with the arrival of direct acting antivirals (DAA) against HCV. Among the first of these new agents are the protease inhibitors telaprevir (TVR) and boceprevir (BOC), which are approved for HCV-1 infection. Data obtained from clinical trials have ...
Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011 ...
Chronic hepatitis C virus (HCV) infection is the leading cause of chronic liver disease. Current therapy using pegylated interferon-α with ribavirin is poorly tolerated and confers an overall sustained virological response around 56%. Compounds exhibiting an improved safety profile with similar or enhanced antiviral properties may represent future treatment options. Several drug discovery programmes are ongoing to directly target the viral enzymes involved in HCV replication. Recent clinical success using a peptidomimetic inhibitor of the viral serine protease has demonstrated proof-of-concept for the use of direct antiviral agents in reducing viral load. The RNA-dependent RNA polymerase (RdRp) of HCV is also required for viral RNA replication and thus represents an attractive drug discovery target. Preclinical characterization of several non-nucleoside inhibitors (NNIs) of the HCV RdRp have been described, including a promising series of benzothiadiazine derivatives which have been shown to ...
Hepatitis B and C in Kidney Transplantation. By Smaragdi Marinaki, Konstantinos Drouzas, Chrysanthi Skalioti and John N. Boletis. The prevalence of chronic hepatitis B and C virus infection has declined among the dialysis population during the past decades. However, it still comprises a major health problem with high morbidity and mortality. Renal transplantation is the optimal treatment for patients with end‐stage renal disease and hepatitis B or C, although it is associated to lower patient and allograft survival compared to seronegative kidney recipients. Novel therapeutic strategies with the use of new antiviral agents, especially direct‐acting antiviral agents in hepatitis C, have significantly changed the natural history of both hepatitis B and C not only in the general population but also in renal‐transplant recipients. We believe that future research should focus on the impact of new antiviral medications in this specific subset of patients.. Part of the book: Advances in Treatment ...
Hepatitis C is a major global health burden with an estimated 160 million infected individuals worldwide. This long-term disease evolves slowly, often leading to chronicity and potentially to liver failure. There is no anti-HCV vaccine, and, until recently, the only treatment available, based on pegylated interferon and ribavirin, was partially effective, and had considerable side effects. With recent advances in the understanding of the HCV life cycle, the development of promising direct acting antivirals (DAAs) has been achieved. Their use in combination with the current treatment has led to encouraging results for HCV genotype 1 patients. However, this therapy is quite expensive and will probably not be accessible for all patients worldwide. For this reason, constant efforts are being made to identify new antiviral molecules. Recent reports about natural compounds highlight their antiviral activity against HCV. Here, we aim to review the natural molecules that interfere with the HCV life cycle and
10. Valtrex works best when the levels in your body are constant. During childbirth it can be transmitted to the baby as it passes through the birth canal, which can cause eye problems (conjunctivitis) if left untreated. It stated that 48 of Black women in the USA have Herpes Type 2; yes, 48this means, half of the Black women in the United States of America. Hi, I have a really painful cold sore up my nose! If you recall, an ex-lover accused him of giving her herpes and sued him because of it. And then theres Derek Jeter whos basically PATIENT ZERO for celebrity herpes.. PS-yes, I understand you have a MASSIVELY powerful team behind you such as JAY-Z and all those guys so you feel safe & keep cascading around town knowing that everything wrong you do, will be covered up. The proanthocyanidins in witch hazel have been shown to exert significant antiviral activity against herpes simplex 1 in the test tube. Her name is marbles. Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir. I read ...
Two groups of antiviral drugs are available for the treatment and prophylaxis of influenza. Antiviral drugs used to treat or prevent influenza are critically important antimicrobials. Acyclovir 400mg capsules and oral solution are indicated for the treatment of chronic hepatitis C in patients 18 years of age and older with compensated liver disease previously untreated with alpha interferon and alpha interferon therapy. Another serious problem with the morden anti-viral medication is that giving antiviral drugs to poultry may leave many countries without low-cost options for treating important emerging viruses in humans. Misuse and overuse of antiviral therapy however increase the risk of resistance. ...
U.S. Food and Drug Administration (FDA) has approved VoseviTM (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated 12 weeks of Vosevi in direct-acting antiviral-experienced chronic HCV-infected patients without cirrhosis or with compensated cirrhosis ...
When a virus infects a person, it hijacks the bodys natural processes in order to fuel its rampage.. A pair of Stanford scientists aims to turn this strength into a weakness and develop what could become a broad-spectrum antiviral drug.. Most antiviral drugs are concocted to act against a specific viral protein. As such, they usually provide a "one drug/one bug" approach.. "Penicillin can kill many types of bacteria, but most antiviral drugs work only against one virus, and sometimes a single subtype of a virus," said Shirit Einav, an assistant professor of medicine and of microbiology and immunology at Stanford School of Medicine.. Additionally, targeting viral proteins is problematic; viruses can mutate quickly, and a single change in the viral sequence can render it fully resistant to the drug.. "With the exception of HIV, we still have very few antiviral drugs to offer patients with viral infections, and even those are often quite limited," Einav said. "No approved antiviral drugs or ...
Definition of antiviral agent in the Fine Dictionary. Meaning of antiviral agent with illustrations and photos. Pronunciation of antiviral agent and its etymology. Related words - antiviral agent synonyms, antonyms, hypernyms and hyponyms. Example sentences containing antiviral agent
TY - JOUR. T1 - Synthesis and antiviral evaluation of polyhalogenated imidazole nucleosides. T2 - Dimensional analogues of 2,5,6-trichloro-1-(β-D-ribofuranosyl) benzimidazole. AU - Chien, Tun Cheng. AU - Saluja, Sunita S.. AU - Drach, John C.. AU - Townsend, Leroy B.. PY - 2004/11/4. Y1 - 2004/11/4. N2 - A series of polyhalogenated imidazole nucleosides were designed and synthesized as ring-contracted analogues of 2,5,6-trichloro-1-(β-D- ribofuranosyl)benzimidazole (TCRB) and its 2-bromo analogue (BDCRB) in an effort to explore the spatial limitation of the active pocket(s) in the target protein(s). 2,4,5-Trichloro-, 2-bromo-4,5-dichloro-, and 2,4,5-tribromoimidazole nucleosides were prepared by a condensation of the preformed heterocycles with the appropriate sugar precursors. The ribofuranosyl and xylofuranosyl analogues were prepared by a direct glycosylation using the Vorbruggens silylation method and provided exclusively the β-anomers. The arabinofuranosyl analogues were prepared by the ...
Read more about New Zika virus inhibitor identified on Business Standard. A new research has brought a drug to treat Zika infections closer to reality.The team led by Alexey Terskikh and Alex Strongin from Sanford Burnham Prebys Medical Discovery Institute (SBP) discovered a compound that prevents the virus from
Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the evaluation of these antibodies in healthy and HIV-1-infected humans. In first clinical trials, highly potent broadly neutralizing antibodies have demonstrated their safety and significant antiviral activity by reducing viremia and delaying the time to viral rebound in individuals interrupting antiretroviral therapy. While emerging antibody-resistant viral variants have indicated limitations of antibody monotherapy, strategies to enhance the efficacy of broadly neutralizing antibodies in humans are under investigation. These include the use of antibody combinations to prevent viral escape, antibody modifications to increase the half-life and the co-administration of latency-reversing agents to target the cellular reservoir of HIV-1. We provide an overview of the results of pre-clinical and clinical studies of broadly HIV-1 ...
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same ...
A trial of an interferon-free regimen of 3 direct-acting antiviral drugs for treatment of hepatitis C virus produced high sustained virologic responses in treatment-naive patients and null responders.
The mucus lining the stomachs of pigs may well be a much awaited, copious source of mucins being regarded for use as wide-ranging anti-viral agents for various purpose report scientists.
Background: Achievement of early viral suppression is important in patients with chronic HCV infection treated with telaprevir (TLV) or boceprevir (BOC) to avoid selection of drug resistance and attain cure. No head-to-head studies comparing TLV and BOC have been performed so far.. Methods: All consecutive individuals who initiated triple HCV therapy with TLV or BOC outside clinical trials at three European clinics were evaluated. Rapid virological response (RVR) was defined as unquantifiable HCV RNA (,25 IU/ml) at week 4 for TLV and at week 8 for BOC (4 weeks after lead-in).. Results: A total of 106 patients were evaluated, 33 treated with BOC and 73 with TLV. Median age, gender, body mass index, baseline HCV RNA, HCV subtype 1a (45% versus 42%) and IL28B-CC alleles (29% versus 23%) did not differ significantly in BOC and TLV groups, respectively. HIV coinfection was more prevalent in patients on TLV than BOC (24% versus 44%). Conversely, more patients on BOC than TLV had previously failed ...
... Friday, June 16, 2017 by: Tracey Watson Tags: DAAs, direct-acting antiviral, hepat
Since the onset of antiviral therapy, viral resistance has compromised the clinical value of small-molecule drugs targeting pathogen components. As intracellular parasites, viruses complete their life cycle by hijacking a multitude of host-factors. Aiming at the latter rather than the pathogen directly, host-directed antiviral therapy has emerged as a concept to counteract evolution of viral resistance and develop broad-spectrum drug classes. This approach is propelled by bioinformatics analysis of genome-wide screens that greatly enhance insights into the complex network of host-pathogen interactions and generate a shortlist of potential gene targets from a multitude of candidates, thus setting the stage for a new era of rational identification of drug targets for host-directed antiviral therapies. With particular emphasis on human immunodeficiency virus and influenza virus, two major human pathogens, we review screens employed to elucidate host-pathogen interactions and discuss the state of database
The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.
The journal focuses on all topics related to hepatoma.Articles in the following areas are especially welcome: Pathogenesis, clinical examination and diagnosis of hepatoma; Complications of hepatoma, and their preventions and treatments etc.
My names Hazel Heal, Im 55 years old. I knew Id had Hep C for many years. I was pregnant and I was very worried about my unborn daughter and we didnt know what it meant and at that time it was considered a bit of a death sentence. It was certainly suggested to me in the hospital when I had my daughter that we wouldnt last long. I hoped that the cures would show up in time and I lived my life. I tried the old treatments and they make you very sick but they didnt cure me. I got the bad news that I was out of time late 2015 and just as I was about to sit my first year law exams. I learned at that time that there were wonderful new drugs, the direct acting antivirals, were available but they werent available in New Zealand at that time and I had to seek them off shore. Ive got to say for myself being cured with direct acting antivirals it was just a complete before and after, my life before, my life after is completely different. What people dont realise is that the price that was being ...
Matthew P. Kosloski, Sandeep Dutta, Weihan Zhao, David Pugatch, Armen Asatryan, Jens Kort, Wei Liu AbbVie Inc., North Chicago, Illinois, United States ...
Zheltkova V, Argilaguet J, Peligero C, Bocharov G, Meyerhans A. Prediction of PD-L1 inhibition effects for HIV-infected individuals. PLOS Computational Biology (2019).. Prochnow H, Rox K, Birudukota NVS, Weichert L, Hotop SK, Klahn P, Mohr K, Franz S, Banda DH, Blockus S, Schreiber J, Haid S, Oeyen M, Martinez JP, Süssmuth RD, Wink J, Meyerhans A, Goffinet C, Messerle M, Schulz TF, Kröger A, Schols D, Pietschmann T, Brönstrup M. Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis. J Virol. (2019). Grebennikov D, Bouchnita A, Volpert V, Bessonov N, Meyerhans A, Bocharov G. Spatial Lymphocite Dynamics in Lymph Nodes Predicts the Cytotoxic T Cell Frequency Needed for HIV Infection Control. Front Immunol. Jun 11;10:1213 (2019).. Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Transl Oncol. Jun;21(6):713-720 (2019).. Argilaguet J, Pedragosa M, Esteve-Codina A, Riera G, ...
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as
Influenza virus can rapidly metamorphose, complicating the effectiveness of vaccines and anti-viral drugs employed in treating it.
Companies developing direct-acting antiviral hepatitis C drugs should factor in interferon treatment when designing clinical trials, the FDA said. Revised draft guidance from the agency on direct-acting antiviral (DAA) development introduced new recommendations for how to design clinical trials around interferon-free drug regimens as well as the impact of combination regimens on patients suffering from a combination of . . .
MK3, a fixed-dose combination of three direct-acting antivirals (DAAs) with different mechanisms of action, provided cure rates exceeding 95% in patients ...
European guidelines issued by the European Association for the Study of the Liver (ELPA) in 2016 recommend that anyone with liver damage or fibrosis stage 2 (moderate liver damage) or above should receive treatment without delay. In most European countries people with cirrhosis and genotypes 1, 3 or 4 are being given priority for treatment with newer interferon-free drug combinations, in order to prevent liver damage progressing further. At this time, in most countries people without moderate-to-severe liver damage and without evidence of fast progression of liver disease are less likely to receive treatment. Treatment recommendations differ according to genotype. Some combinations of direct-acting antivirals are active against all, or several, HCV genotypes. These are called pan- genotypic drugs. Other direct-acting antivirals are only active against genotype 1.. The table below outlines European recommendations for the treatment of each genotype issued in September 2016. Access to these drugs ...
The Lens serves almost all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.
Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. The chemical foundation of the approved and late-stage HCV NS3 protease inhibitors is markedly similar. This could partly explain the cross-resistance that have emerged under the pressure of NS3 protease inhibitors. The first-generation NS3 protease inhibitors were developed to efficiently inhibit genotype 1 of the virus and were less potent against other genotypes.. The main focus in this thesis was to design and synthesize a new class of 2(1H)-pyrazinone based HCV NS3 protease inhibitors, structurally dissimilar to the inhibitors evaluated in clinical trials or approved, potentially with a unique resistance profile and with a broad genotypic coverage. Successive ...
TY - JOUR. T1 - Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells. AU - Feorino, P. M.. AU - Butera, S. T.. AU - Folks, T. M.. AU - Schinazi, R. F.. PY - 1993. Y1 - 1993. N2 - The development of a reliable and simple system for evaluating compounds that could prevent activation of latent HIV would allow us to devise new therapeutic approaches. These compounds could eventually be used in combination with drugs that are effective against acute and chronic infections. The OM-10.1 cell line is a chronically infected clone which remains CD4+ until HIV-1 activation with tumour necrosis factor-α. A variety of compounds are known to have antiviral properties against either acutely or chronically infected cells were evaluated for their ability to inhibit HIV induced expression in these cells. We also examined the effect of several compounds that interact with biochemical pathways that may interfere with or enhance the reactivation process. These included nucleoside analogues, ...
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target side-effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as ...
The advent of user friendly and highly successful oral regimens based on direct antiviral agents (DAA), has made a cure of hepatitis C possible in more than 95% of treated patients, including those who were considered difficult to cure with interferon, a vast category including patients with advanced liver disease and those who had a hepatocellular carcinoma (HCC) successfully eradicated by resection or local ablation1 . Despite low rates of treatment uptake and response to therapy with interferon, such hard to treat patients were able to gain significant health benefits, like halting of progression towards liver failure and prevention of second primary tumours, once replication of the hepatitis C virus (HCV) was permanently shut down2,3 ...
Sirona Biochem Initiates COVID-19 and Infectious Diseases Development Program. Vancouver, BC, April 1, 2020--Sirona Biochem Corp. (TSX-V: SBM) announced that its French subsidiary lab TFChem has initiated an antiviral program to produce potential new antiviral agents to assist in combating COVID-19 and other infectious diseases.
This type of real world study is absolutely essential to understand how the drugs will perform outside of clinical trials. The data and samples are already being analysed so we can answer some essential questions about how efficient these new drugs are and which patients may benefit the most from receiving them.. What are or will be the latest significant advances in HCV research? How close or how far away are we from a Hepatitis C vaccine?. Having a cheap, readily available vaccine to prevent HCV infection would be a holy grail for the entire field. How far away we are from having a vaccine is difficult to judge but there are many groups, including those at the CVR, who are actively looking at new approaches.. To some extent, it is similar to a vaccine against HIV; there have been promising candidates but all have failed and so we have to rely on antiviral drugs. The difference with HCV compared to HIV infection is that the drugs do clear the virus while for HIV, they will only suppress ...
NVR 3-778 is the first capsid assembly modulator (CAM) that has demonstrated antiviral activity in hepatitis B virus (HBV)-infected patients. NVR 3-778 inhibited the generation of infectious HBV DNA-containing virus particles with a mean antiviral 50% effective concentration (EC50) of 0.40 µM in HepG2.2.15 cells. ...
In order to better understand the source(s) and the mechanism(s) of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs, we propose to examine the effect of co-administration of enfuvirtide, an entry inhibitor of HIV, on diminution of the size of the viral reservoir in infected individuals who are receiving effective antiviral therapy for extended periods of time (, 5 years ...